Oncolytics Biotech Inc. (ONCY), a clinical-stage company, announced on Thursday positive clinical outcomes from its BRACELET-1 trial, a randomized Phase 2 study evaluating the efficacy of pelareorep in patients with HR+/HER2- advanced or metastatic breast cancer.
The final efficacy data from BRACELET-1 was collected and analyzed two years after the last patient enrollment, as outlined by the study protocol.
The results of the final analysis indicated that the median overall survival (OS) was not reached in the pelareorep plus paclitaxel cohort, with over half of the patients in that group still alive at the conclusion of the study.
Conversely, the paclitaxel monotherapy group had a median OS of 18.2 months, with a hazard ratio of 0.48 when comparing the pelareorep plus paclitaxel arm to the monotherapy arm.
“The fact that the median overall survival was not reached due to over half of the patients being alive at the end of the study is a remarkable milestone for us,” stated Wayne Pisano, Interim CEO and Chair of Oncolytics' Board of Directors. “It illustrates the potential of pelareorep treatment in significantly extending the lives of breast cancer patients. This is further highlighted by the near doubling of the 2-year survival rate for patients treated with the pelareorep combination therapy.”
